Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Naïma Hanoun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-8511-4788; OpenAlex author ID A5121757669. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 10

  1. A genome-wide CRISPR-Cas9 screen identifies TGN46 as a host determinant for H-1PV susceptibility in pancreatic adenocarcinoma Co-author DOI 10.64898/2026.03.06.710102↗
  2. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1038/s41598-024-76903-y↗
  3. Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. Co-author DOI 10.1038/s42003-024-06760-y↗
  4. Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. Co-author DOI 10.1158/0008-5472.can-22-3219↗
  5. Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.omtm.2023.03.005↗
  6. Cytidine deaminase regulates mitochondrial biogenesis in pancreatic cancer cells Co-author DOI 10.1101/2022.12.15.520429↗
  7. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Co-author DOI 10.1089/hum.2015.151↗
  8. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Co-author DOI 10.1038/mt.2015.1↗
  9. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic… Co-author DOI 10.1097/mcg.0000000000000053↗
  10. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. Co-author DOI 10.1371/journal.pone.0055513↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Louis Buscail · 10 shared papers, 2013–2026 · strength 1.34
  2. Pierre Cordelier · 10 shared papers, 2013–2026 · strength 1.34
  3. Nelson Dusetti · 4 shared papers, 2022–2026 · strength 0.77
  4. Marion Gayral · 5 shared papers, 2015–2024 · strength 0.57
  5. Jérôme Torrisani · 5 shared papers, 2013–2024 · strength 0.53
  6. Guillaume Labrousse · 2 shared papers, 2024–2026 · strength 0.47
  7. Audrey Lumeau · 3 shared papers, 2022–2024 · strength 0.46
  8. Audrey Francès · 3 shared papers, 2022–2024 · strength 0.46
  9. Barbara Bournet · 3 shared papers, 2015–2024 · strength 0.27
  10. Odile Barbey · 2 shared papers, 2015–2023 · strength 0.21
  11. Emmanuel Cuellar · 1 shared paper, 2024 · strength 0.18
  12. Fabrice Muscari · 1 shared paper, 2024 · strength 0.18
  13. Charlotte Maulat · 1 shared paper, 2024 · strength 0.18
  14. Cindy Canivet · 1 shared paper, 2024 · strength 0.18
  15. Abdessamad El Kaoutari · 1 shared paper, 2024 · strength 0.15
  16. Flavie Sicard · 1 shared paper, 2013 · strength 0.04
  17. Yannick Delpu · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.